Case-Based Learning on Balancing Therapeutic Priorities in Frail Adults With Polypharmacy

Abstract

Frail older adults frequently navigate complex therapeutic landscapes due to multimorbidity and polypharmacy, presenting unique challenges for clinicians aiming to optimize outcomes and minimize adverse effects. This review examines the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management of polypharmacy in frail adults, integrating recent evidence and guidelines. Emphasis is placed on practical, case-based strategies to balance therapeutic priorities, mitigate risks, and tailor interventions for this vulnerable population.

Introduction

Polypharmacy, defined as the concurrent use of multiple medications, is a prevalent and often necessary feature of care in frail older adults with multiple comorbidities. However, it is associated with increased risks of adverse drug events (ADEs), hospitalizations, and functional decline. Balancing therapeutic priorities requires a nuanced, patient-centered approach, informed by evolving clinical evidence and guidelines. This article provides an in-depth, case-based review to guide clinicians in optimizing pharmacotherapy for frail adults while minimizing harm.

Epidemiology / Disease Burden

Polypharmacy affects over 40% of adults aged 65 and older, with higher rates observed in those classified as frail. The prevalence of frailty itself ranges from 10% to 20% in community-dwelling older adults, rising to over 40% in institutionalized populations. Studies indicate that frail individuals are prescribed an average of seven or more medications, increasing their susceptibility to drug-drug interactions, ADEs, and healthcare utilization. The burden of polypharmacy is compounded by age-related changes in pharmacokinetics and pharmacodynamics, as well as the presence of geriatric syndromes such as cognitive impairment and falls.

Pathophysiology

Frail adults experience physiological decline across multiple organ systems, including reduced renal and hepatic function, altered body composition, and impaired homeostatic mechanisms. These changes affect drug absorption, distribution, metabolism, and excretion, amplifying the risks of polypharmacy. Frailty itself is driven by chronic inflammation, sarcopenia, and decreased reserve, rendering individuals less resilient to the physiological stressors imposed by medications. Polypharmacy can accelerate frailty progression by increasing the risk of delirium, falls, malnutrition, and functional decline.

Risk Factors

Key risk factors for polypharmacy in frail adults include advanced age, multimorbidity, cognitive impairment, frequent transitions of care, and inadequate medication reconciliation. Social determinants such as limited health literacy, fragmented care, and lack of caregiver support further increase vulnerability. The risk is heightened in patients with chronic diseases such as heart failure, diabetes, and chronic kidney disease, which often require complex regimens involving multiple drug classes.

Clinical Features

Clinical manifestations of problematic polypharmacy in frail adults are diverse and often nonspecific. Presentations can include falls, confusion, functional decline, orthostatic hypotension, incontinence, and unexplained weight loss. Subtle signs such as reduced appetite, fatigue, or behavioral changes may be the only clues to medication-related harm. Comprehensive geriatric assessment is essential to identify the interplay between medications and geriatric syndromes, facilitating early recognition of adverse effects.

Diagnosis

Diagnosis of polypharmacy-related complications relies on a thorough medication review, including prescription, over-the-counter, and herbal products. Tools such as the Beers Criteria and STOPP/START criteria are invaluable in identifying potentially inappropriate medications. The evaluation should encompass assessment of renal and liver function, cognitive status, and functional capacity. A multidisciplinary approach involving pharmacists, physicians, and nursing staff enhances the detection of drug-related problems and supports individualized deprescribing.

Treatment & Management

Optimal management of polypharmacy in frail adults requires a structured, patient-centered approach. Key steps include regular medication reconciliation, prioritization of therapeutic goals, and shared decision-making. Deprescribing—systematic discontinuation of unnecessary or harmful medications—is central to reducing pill burden and adverse outcomes. Non-pharmacologic interventions, such as physical therapy and social support, should be integrated into care plans. Clinicians must balance the benefits and harms of each medication, considering life expectancy, patient preferences, and quality of life.

Recent Advances / Emerging Therapies

Recent research emphasizes the value of electronic decision-support tools, pharmacist-led interventions, and interprofessional case conferences in reducing inappropriate polypharmacy. Emerging strategies include the application of pharmacogenomics to personalize therapy and minimize drug reactions. Studies such as the OPTIMIZE and SENATOR trials demonstrate that tailored interventions can reduce ADEs and improve functional outcomes. Ongoing research is exploring the use of artificial intelligence to predict risk and guide deprescribing processes.

Guideline Recommendations

Current guidelines from organizations such as the American Geriatrics Society and the European Geriatric Medicine Society advocate for routine medication review and deprescribing in frail older adults. Recommendations underscore the importance of individualized care plans, explicit documentation of therapeutic goals, and frequent reassessment of medication necessity. Shared decision-making, involving patients and caregivers, is highlighted as essential for aligning therapy with patient values and preferences.

Conclusion

Balancing therapeutic priorities in frail adults with polypharmacy is a complex, dynamic process requiring multidisciplinary collaboration and ongoing assessment. Clinicians must integrate clinical expertise, evidence-based guidelines, and patient preferences to optimize outcomes while minimizing harm. Advances in technology and personalized medicine offer promising avenues for improving care, but the cornerstone remains thoughtful, patient-centered decision-making supported by regular medication review and deprescribing when appropriate.